News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD) Battles To Shift Debate Over $1,000 Hepatitis Pills From Costs To Cures



8/5/2014 6:33:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

When Gilead Sciences Inc. President John Milligan recently told Wall Street analysts that he expected more stories centering on the growing number of patients benefitting from the company’s pricey hepatitis C drug Sovaldi, he wasn’t kidding.

New hepatitis C treatments, including Foster City-based Gilead’s $1,000-a-pill cure, could save the lives of tens of thousands of people, concludes a report released last week by the California Healthcare Institute. But the report doesn’t address pricing of Gilead’s drug, Sovaldi, or oncoming hep C drugs or the impact of those drugs on government and private insurance programs.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES